Mark J. Rosenblum
2021 - Flex Pharma
In 2021, Mark J. Rosenblum earned a total compensation of $442K as Executive Vice President, Finance and Chief Financial Officer at Flex Pharma, a 15% decrease compared to previous year.
Compensation breakdown
| Bonus | $152,374 |
|---|---|
| Salary | $278,360 |
| Other | $11,275 |
| Total | $442,010 |
Rosenblum received $278.4K in salary, accounting for 63% of the total pay in 2021.
Rosenblum also received $152.4K in bonus and $11.3K in other compensation.
Rankings
In 2021, Mark J. Rosenblum's compensation ranked 10,986th out of 12,415 executives tracked by ExecPay. In other words, Rosenblum earned more than 11.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,986 out of 12,415 | 12th |
Division Manufacturing | 4,848 out of 5,508 | 12th |
Major group Chemicals And Allied Products | 2,165 out of 2,378 | 9th |
Industry group Drugs | 1,926 out of 2,099 | 8th |
Industry Pharmaceutical Preparations | 1,426 out of 1,549 | 8th |
Source: SEC filing on April 28, 2022.
Rosenblum's colleagues
We found one more compensation record of an executive who worked with Mark J. Rosenblum at Flex Pharma in 2021.
2021
David Arthur
Flex Pharma